Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant

Abstract

Background SARS-CoV-2 is a RNA coronavirus responsible for the pandemic of the Severe Acute Respiratory Syndrome (COVID-19). RNA viruses are characterized by a high mutation rate, up to a million times higher than that of their hosts. Virus mutagenic capability depends upon several factors, including the fidelity of viral enzymes that replicate nucleic acids, as SARS-CoV-2 RNA dependent RNA polymerase (RdRp). Mutation rate drives viral evolution and genome variability, thereby enabling viruses to escape host immunity and to develop drug resistance. Methods We analyzed 220 genomic sequences from the GISAID database derived from patients infected by SARS-CoV-2 worldwide from December 2019 to mid-March 2020. SARS-CoV-2 reference genome was obtained from the GenBank database. Genomes alignment was performed using Clustal Omega. Mann–Whitney and Fisher-Exact tests were used to assess statistical significance. Results We characterized 8 novel recurrent mutations of SARS-CoV-2, located at positions 1397, 2891, 14408, 17746, 17857, 18060, 23403 and 28881. Mutations in 2891, 3036, 14408, 23403 and 28881 positions are predominantly observed in Europe, whereas those located at positions 17746, 17857 and 18060 are exclusively present in North America. We noticed for the first time a silent mutation in RdRp gene in England (UK) on February 9th, 2020 while a different mutation in RdRp changing its amino acid composition emerged on February 20th, 2020 in Italy (Lombardy). Viruses with RdRp mutation have a median of 3 point mutations [range: 2–5], otherwise they have a median of 1 mutation [range: 0–3] (p value < 0.001). Conclusions These findings suggest that the virus is evolving and European, North American and Asian strains might coexist, each of them characterized by a different mutation pattern. The contribution of the mutated RdRp to this phenomenon needs to be investigated. To date, several drugs targeting RdRp enzymes are being employed for SARS-CoV-2 infection treatment. Some of them have a predicted binding moiety in a SARS-CoV-2 RdRp hydrophobic cleft, which is adjacent to the 14408 mutation we identified. Consequently, it is important to study and characterize SARS-CoV-2 RdRp mutation in order to assess possible drug-resistance viral phenotypes. It is also important to recognize whether the presence of some mutations might correlate with different SARS-CoV-2 mortality rates.

Cited by papers we hold 19

• A Detailed Overview of Immune Escape, Antibody Escape, Partial Vaccine Escape of SARS-CoV-2 and Their Emerging Variants With Escape Mutations · 2022
  No notice
• Mutations in the SARS-CoV-2 RNA-dependent RNA polymerase confer resistance to remdesivir by distinct mechanisms · 2022
  No notice
• Detailed phylogenetic analysis tracks transmission of distinct SARS-COV-2 variants from China and Europe to West Africa · 2021
  Not checked
• Symptomatic manifestations of the disease caused by coronavirus (COVID-19) in adults: systematic review · 2021
  Not checked
• Genome-wide identification and prediction of SARS-CoV-2 mutations show an abundance of variants: Integrated study of bioinformatics and deep neural learning · 2021
  Not checked
• Emerging Severe Acute Respiratory Syndrome Coronavirus 2 Mutation Hotspots Associated With Clinical Outcomes and Transmission · 2021
  Not checked
• Rapid electrochemical detection of coronavirus SARS-CoV-2 · 2021
  No notice
• Emerging SARS-CoV-2 variants of concern and potential intervention approaches · 2021
  No notice
• The Global Epidemic of the SARS-CoV-2 Delta Variant, Key Spike Mutations and Immune Escape · 2021
  No notice
• Analysis of SARS-CoV-2 mutations in the United States suggests presence of four substrains and novel variants · 2021
  Corrected
• Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past · 2020
  No notice
• Integrative analyses of SARS-CoV-2 genomes from different geographical locations reveal unique features potentially consequential to host-virus interaction, pathogenesis and clues for novel therapies · 2020
  Not checked
• Bioinformatic prediction of potential T cell epitopes for SARS-Cov-2 · 2020
  No notice
• Evolutionary and structural analyses of SARS-CoV-2 D614G spike protein mutation now documented worldwide · 2020
  No notice
• Targeting the NLRP3 Inflammasome in Severe COVID-19 · 2020
  No notice
• Genome-wide analysis of SARS-CoV-2 virus strains circulating worldwide implicates heterogeneity · 2020
  Corrected
• SARS-CoV-2/COVID-19: Viral Genomics, Epidemiology, Vaccines, and Therapeutic Interventions · 2020
  No notice
• Stability of SARS-CoV-2 phylogenies · 2020
  No notice
• Understanding SARS‐CoV‐2 endocytosis for COVID‐19 drug repurposing · 2020
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.